8-K: Cadrenal's CAD-1005 Shows Encouraging Thrombotic Event Reduction

Cadrenal Therapeutics announced encouraging Phase 2 results for CAD-1005 in heparin-induced thrombocytopenia (HIT), showing a 25% absolute reduction in thrombotic events despite missing its primary endpoint.

Summary

• Phase 2 trial for CAD-1005 in heparin-induced thrombocytopenia (HIT) showed encouraging results in reducing thrombotic events.
• The primary endpoint, platelet count recovery rate, was not met, with similar rates observed in both CAD-1005 and placebo arms. Platelet count recovery was deemed not a suitable surrogate marker for clinical efficacy.
• A key secondary endpoint revealed a high rate of thrombotic events (>75%) in the placebo group, compared to 50% in the CAD-1005 group, representing a greater than 25% absolute reduction.
• The study was not statistically powered to detect significance for the secondary endpoint due to its design by the previous sponsor, Veralox Therapeutics.
• Cadrenal Therapeutics has scheduled an End-of-Phase 2 (EOP2) meeting with the FDA for March 2026 to discuss a Phase 3 registration path.
• CAD-1005 is a selective inhibitor of 12-lipoxygenase (12-LOX), targeting the underlying immune mechanisms of HIT, and is the only 12-LOX inhibitor in clinical development worldwide.
• HIT is a life-threatening immune-mediated complication of heparin, affecting over 12 million patients annually in the U.S., with mortality rates exceeding 20%.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development given the significant reduction in thrombotic events, which is a critical clinical outcome for HIT, despite the primary endpoint miss. The FDA meeting is a key de-risking step.

Positives

• CAD-1005 demonstrated a greater than 25% absolute reduction in thrombotic events compared to placebo (50% vs. >75%) in HIT patients.
• The encouraging trend in reducing thrombotic events supports the company's decision to acquire and rapidly progress CAD-1005's development.
• CAD-1005 is the only 12-LOX inhibitor in clinical development globally, offering a novel approach to HIT by targeting its immune drivers.
• The company has secured an End-of-Phase 2 (EOP2) meeting with the FDA in March 2026, a significant milestone for advancing to Phase 3.
• CAD-1005 has received Orphan Drug Designation and Fast Track designation from the U.S. FDA, and orphan drug status from the European Medicines Agency.
• Preclinical models and healthy human volunteer studies showed CAD-1005 did not increase bleeding risk.

Negatives

• The Phase 2 trial did not meet its primary endpoint of platelet count recovery rate, with similar rates observed between CAD-1005 and placebo arms.
• The study was not statistically powered to detect significance for the observed reduction in thrombotic events, which was a secondary endpoint.
• The study was stopped early in December 2025 after program ownership transfer, resulting in a smaller final dataset of 24 patients (17 confirmed HIT patients) than originally planned (60 patients).

Risks

• The ability to advance the clinical development of CAD-1005 for HIT, including designing a pivotal Phase 3 registration study acceptable to the FDA.
• CAD-1005's ability to effectively address the underlying immune mechanism and the unmet medical need for the serious thrombotic disorder.
• The ability to successfully complete clinical trials on time and achieve desired results and benefits, including support for CAD-1005's potential to be a treatment option for HIT.
• The ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements.
• Actual results may differ materially from forward-looking statements due to various important factors, as described in the company's SEC filings.

Future Outlook

The company plans to leverage the encouraging secondary endpoint results to align with the FDA on a Phase 3 registration path during an End-of-Phase 2 meeting scheduled for March 2026. Management believes CAD-1005 could represent a major step forward as the only first-line therapy targeting the immune mechanisms responsible for HIT and is enthusiastic about its potential to address the unmet medical need for this serious thrombotic disorder. Detailed trial results will be presented at a future scientific meeting.

Management Comments

• "The encouraging trend toward reduced thrombotic events in the CAD-1005 treatment arm is strong support for the company's decision to acquire this asset and rapidly progress its development." Quang X. Pham, CEO of Cadrenal Therapeutics.
• "Inhibition of 12-LOX is an exciting therapeutic frontier, potentially targeting numerous inflammatory, thrombotic, and metabolic conditions." Quang X. Pham, CEO of Cadrenal Therapeutics.
• "First, platelet count recovery was not an appropriate surrogate endpoint for clinical efficacy in a trial in which standard therapy event rates were strikingly high. Secondly, despite the relatively small number of patients, the reduction in thrombotic events with CAD-1005 is extremely encouraging." James Ferguson, MD, Chief Medical Officer of Cadrenal Therapeutics.
• "CAD-1005 could represent a major step forward as the only first-line therapy targeting the immune mechanisms responsible for HIT." James Ferguson, MD, Chief Medical Officer of Cadrenal Therapeutics.
• "We are enthusiastic about CAD-1005 in addressing both the underlying immune mechanism and the unmet medical need for this serious thrombotic disorder." Steven E. McKenzie, MD, PhD, Professor of Medicine at Thomas Jefferson University and a member of the study steering committee.

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry is constantly seeking novel therapies for life-threatening conditions with high unmet medical needs. Heparin-induced thrombocytopenia (HIT) represents such a condition, with high mortality rates and current treatments primarily focused on preventing thrombotic complications rather than addressing the underlying immune drivers. CAD-1005's unique mechanism as a 12-LOX inhibitor positions it as a potential first-in-class therapy, differentiating it from existing anticoagulants and offering a new therapeutic approach in a market where over 12 million patients receive heparin annually in the U.S. The focus on immune mechanisms aligns with broader trends in precision medicine.

Comparison to Industry Standards

• Current standard anticoagulant therapies for HIT, such as argatroban or bivalirudin, primarily aim to prevent thrombotic complications. CAD-1005 differentiates itself by targeting the underlying immune mechanisms, a novel approach not currently offered by other treatments in clinical development for HIT.
• The filing highlights that the field of HIT treatment is "full of anticoagulant use in the absence of randomized prospective trials," suggesting that CAD-1005's blinded placebo-controlled trial, despite its limitations, provides a more robust evidence base than much of the existing practice.
• While the study was not powered for statistical significance, the observed 25% absolute reduction in thrombotic events (50% in CAD-1005 vs. >75% in placebo) is a clinically meaningful difference, especially given the high mortality rates (exceeding 20%) associated with HIT complications like deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction.

Stakeholder Impact

• Shareholders: Potential for increased value if CAD-1005 successfully progresses through clinical trials and gains regulatory approval, given the encouraging secondary endpoint results and novel mechanism.
• Patients with HIT: Potential for a new, more effective treatment option that targets the underlying cause of their life-threatening condition, potentially reducing thrombotic events and improving outcomes.
• Healthcare Providers: Could offer a new therapeutic tool for managing HIT, especially if it proves superior to existing standard anticoagulants in preventing thrombotic complications.
• Regulatory Authorities (FDA, EMA): Engagement through Orphan Drug, Fast Track designations, and the upcoming EOP2 meeting indicates active collaboration and potential for expedited review.

Next Steps

• End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) scheduled for March 2026 to align on a Phase 3 registration path.
• Detailed trial results will be presented at a future scientific meeting.
• Continued clinical development of CAD-1005 for the treatment of HIT.
• Advancing second-generation 12-LOX oral therapeutics.
• Further development of tecarfarin (Phase 3-ready) and frunexian (clinical-stage Factor XIa inhibitor).

Key Dates

Recommendation

The results are encouraging for the secondary endpoint, showing a clinically meaningful reduction in thrombotic events, which is a strong positive for a severe condition like HIT. However, the primary endpoint was missed, and the study was not powered for statistical significance on the secondary endpoint. The upcoming FDA meeting is a critical de-risking event. Given the mixed results and the need for further clarity on the Phase 3 path, a "hold" recommendation is appropriate for investors to await the outcome of the FDA meeting and further trial design details before making a more definitive investment decision. The potential is significant, but so is the remaining clinical and regulatory risk.

Keywords

Cadrenal Therapeutics, CVKD, CAD-1005, Heparin-Induced Thrombocytopenia, HIT, 12-LOX inhibitor, Phase 2 trial, Thrombotic events, FDA, Orphan Drug Designation, Fast Track, Biopharmaceutical, Clinical development, Anticoagulant